Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ignacio Inglessis-Azuaje

Cardiovascular Disease Boston, MA Medical Doctor

NPI 1134186927 CMS profile 323303

55 Fruit St, Grb 852C Cardiac Unit Associates, Boston, MA 02114

Open in the dashboard

General payments

$545,230

773 records reported · program years 2019–2025

Research payments

$17,925

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,961,285 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ignacio Inglessis-Azuaje of Boston, MA is reported in the CMS Open Payments database as having received $545,230 across 773 general payments and $17,925 in research payments paid to them. Separately, studies naming them as principal investigator received $2,961,285 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $65,249 113
2024 General $64,352 99
2023 General $123,854 154
2022 General $64,349 115
2022 Research $4,800 1
2021 General $34,333 64
2021 Research $12,375 2
2020 General $78,221 57
2019 General $114,871 171
2019 Research $750 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ignacio Inglessis-Azuaje
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ignacio Inglessis-Azuaje were reported at $65,249. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ignacio Inglessis-Azuaje Cardiovascular Disease median Middle half National median
2019 $114,871 $450 $127–$1,392 $163
2020 $78,221 $242 $77–$751 $114
2021 $34,333 $335 $101–$1,037 $132
2022 $64,349 $395 $121–$1,211 $149
2023 $123,854 $443 $136–$1,283 $160
2024 $64,352 $450 $136–$1,323 $164
2025 $65,249 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $229,986 312 payments
  2. W. L. Gore & Associates, Inc. $120,168 91 payments
  3. Medtronic, Inc. $58,272 164 payments
  4. Medtronic Vascular, Inc. $57,067 80 payments
  5. Abbott Laboratories $44,620 65 payments
  6. Boston Scientific Corporation $21,009 48 payments
  7. Shockwave Medical, Inc $13,060 8 payments
  8. Abiomed $576 1 payment
  9. Ancora Heart, Inc. $234 1 payment
  10. Merit Medical Systems Inc $200 1 payment
  11. Other $37 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $335,974 91 payments
  2. Travel and Lodging $80,971 310 payments
  3. Honoraria $51,959 11 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $37,763 18 payments
  5. Food and Beverage $21,813 337 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $16,750 6 payments
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $137,701 152 payments
  2. Edwards SAPIEN 3 Transcatheter Heart Valve $55,944 67 payments
  3. CARDIOFORM Septal Occluder $51,033 33 payments
  4. GORE CARDIOFORM Septal Occluder $47,190 36 payments
  5. GORE CARDIOFORM ASD Occluder $34,305 20 payments
  6. AMPLATZER Occluders $23,783 18 payments
  7. PASCAL $23,355 32 payments
  8. CoreValve Evolut $17,354 24 payments
  9. COREVALVE EVOLUT R $15,969 39 payments
  10. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $13,060 8 payments
  11. Other $61,410 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $17,175 3 payments
  2. Medtronic Vascular, Inc. $750 2 payments

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$194,159

Medicare's payments for the services billed

Medicare patients

402

Average age 78

Services billed

1,352

161 women, 241 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Heart failure 61%
Atrial fibrillation 52%
Arthritis 46%
Chronic kidney disease 41%
Diabetes 33%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

778 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record